首页> 外文OA文献 >N(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

【2h】

N(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

机译：N（嘧啶-2-基）-1,2,3,4-四羟基喹啉-6-胺衍生物作为选择性Janus激酶2抑制剂，用于治疗髓原瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 -1
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Correction to “N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms” [J] . Tao Yang, Mengshi Hu, Yong Chen, Journal of Medicinal Chemistry . 2021,第4期

机译：校正“N-（嘧啶-2-基）-1,2,3,4-四羟基喹啉-6-胺衍生物作为选择性Janus激酶2抑制剂，用于治疗Myeloproiferative肿瘤”
2. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms (vol 62, pg 10305, 2019) [J] . Yang Tao, Hu Mengshi, Qi Wenyan, Journal of Medicinal Chemistry . 2020,第3期

机译：发现有效和口服有效的双janus激酶2 / flt3抑制剂，用于治疗急性髓性白血病和myeloproiferative肿瘤（Vol 62，Pg 10305,2019）
3. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms [J] . Yang Tao, Hu Mengshi, Qi Wenyan, Journal of Medicinal Chemistry . 2019,第22期

机译：发现有效和口服有效的双janus激酶2 / flt3抑制剂，用于治疗急性髓性白血病和myeloproiferative肿瘤
4. Pyrrolo2,3-dpyrimidine and Pyrazolo3,4-dpyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase [C] . G. Caravatti, J. Bruggen, E. Buchdunger, American Chemical Society . 2001

机译：Pyrrolo 2,3-D嘧啶和吡唑3,4-D嘧啶衍生物作为EGF受体酪氨酸激酶的选择性抑制剂
5. Transcriptional and Proteomic Changes Associated with the Sensitivity and Resistance to JAK2 Inhibitors: Implications for the Treatment of BCR-ABL (-) Myeloproliferative Neoplasms (MPNs). [D] . McDevitt, Theresa Marie. 2012

机译：与JAK2抑制剂的敏感性和抗性相关的转录和蛋白质组学变化：对BCR-ABL（-）骨髓增生性肿瘤（MPNs）的治疗意义。
6. Discovery and evaluation of ZT55 a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms [O] . Min Hu, Chengbo Xu, Chao Yang, 2019

机译：发现和评估ZT55JAK2V617F的新型高选择性酪氨酸激酶抑制剂可抑制骨髓增生性肿瘤
7. Correction to “Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms” [O] . Tao Yang, Mengshi Hu, Wenyan Qi, 2020

机译：“发现有效和口服有效的双janus激酶2 / flt3抑制剂治疗急性髓性白血病和myeloproiferative neoplasms的校正”

N(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

著录项

引文网络

相似文献

相关主题

期刊订阅